Innovations in artificial intelligence are transforming oncology diagnostics and drug discovery. Imagene AI secured $23 million in Series B funding to advance multimodal digital pathology models that integrate histopathology and molecular data, optimizing clinical trial design and patient management. Concurrently, researchers developed AI models predicting five-year survival in hepatocellular carcinoma and early pancreatic cancer progression, offering enhanced prognostic precision. These advances underscore AI’s critical role in personalized medicine and precision oncology.